US OptionsDetailed Quotes
ALUR241220P5000
- 0.00
- 0.000.00%
15min DelayClose Nov 27 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-1165.82%PremiumDec 20, 2024Expiry Date4.61Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.09Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Allurion Technologies Stock Discussion
Sign in to post a comment
I WILL UPDATE IF I FIND MORE
$Poseida Therapeutics (PSTX.US)$ ✔️TOP PLAY. To be acquired by Roche for $1.5B for $9.00/share. “Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash”
$Citius Pharmaceuticals (CTXR.US)$✔️ News halt after hours + PR today o...
$Poseida Therapeutics (PSTX.US)$ ✔️TOP PLAY. To be acquired by Roche for $1.5B for $9.00/share. “Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash”
$Citius Pharmaceuticals (CTXR.US)$✔️ News halt after hours + PR today o...
41
11
$Allurion Technologies (ALUR.US)$ Allurion Launches AllurionMeds In The U.S., Combining AI-Driven GLP-1 Weight Loss Program With Coach Iris For Long-Term Maintenance, Expanding Reach To All 50 States And Advancing Mission To Combat Obesity
Benzinga· 2 mins ago
Benzinga· 2 mins ago
$Cadence Design Systems (CDNS.US)$ $Atlas Lithium (ATLX.US)$ $Intelligent Group (INTJ.US)$ $Allurion Technologies (ALUR.US)$ $Sky Quarry (SKYQ.US)$ $Nixxy (NIXX.US)$ $Vicinity Motor (VEV.US)$ $F5 Inc (FFIV.US)$ $VF Corp (VFC.US)$ $Live Ventures (LIVE.US)$ $Alaunos Therapeutics (TCRT.US)$ $Gulf Resources (GURE.US)$ $Shuttle Pharmaceuticals (SHPH.US)$
📊⚡️📊
📊⚡️📊
2
$Allurion Technologies (ALUR.US)$ Reuters· 3 mins ago
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
1
3
$Allurion Technologies (ALUR.US)$
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
Allurion Technologies (NYSE: ALUR) has announced the publication of a meta-analysis demonstrating the safety and effectiveness of the Allurion Program for weight loss. The systematic review, which analyzed 11 studies involving 2,107 patients conducted between 2016 and 2024, reported an average weight reduction of 12.5% and a sign...
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
Allurion Technologies (NYSE: ALUR) has announced the publication of a meta-analysis demonstrating the safety and effectiveness of the Allurion Program for weight loss. The systematic review, which analyzed 11 studies involving 2,107 patients conducted between 2016 and 2024, reported an average weight reduction of 12.5% and a sign...
1
Here's how it looks like while me sitting in the cafe waiting for customers & online orders during the midweek 😃 ☕ 🌯
Lot to catch up and learn. 🫠
#weemorning #shareyourprofitloss
Lot to catch up and learn. 🫠
#weemorning #shareyourprofitloss
loading...
27
15
$Allurion Technologies (ALUR.US)$ why it is not moving
$Allurion Technologies (ALUR.US)$
Allurion Receives Continued Listing Standards Notice from NYSE
Allurion Receives Continued Listing Standards Notice from NYSE
$Allurion Technologies (ALUR.US)$
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
Allurion Technologies (NYSE: ALUR) has published a study on the safety and effectiveness of the Allurion Program in adolescents with obesity. The study involved 91 adolescents aged 15-17 with an average BMI of 35.6. Key findings include:
- Average weight reduction of 13.1% four months after balloon placement
- No serious adverse events or early device re...
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
Allurion Technologies (NYSE: ALUR) has published a study on the safety and effectiveness of the Allurion Program in adolescents with obesity. The study involved 91 adolescents aged 15-17 with an average BMI of 35.6. Key findings include:
- Average weight reduction of 13.1% four months after balloon placement
- No serious adverse events or early device re...
1
$Allurion Technologies (ALUR.US)$
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
Allurion Technologies (NYSE: ALUR) has published a study showing impressive weight loss results with its Allurion Program. 486 patients achieved an average weight reduction of 10.5% at four months, improving to 13.7% at one year. The program combines the Allurion Balloon with virtual guidance and support, including monthly assessments using the A...
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
Allurion Technologies (NYSE: ALUR) has published a study showing impressive weight loss results with its Allurion Program. 486 patients achieved an average weight reduction of 10.5% at four months, improving to 13.7% at one year. The program combines the Allurion Balloon with virtual guidance and support, including monthly assessments using the A...
No comment yet
Nilco : thanks again jag. appreciate your work.
Yang Zheng107 : thx lot
WILLEE9ice : awesome
Con12346 : Thank you very much.
winstontwh : Thanks for this Jag. Appreciate it
View more comments...